Abstract
This Viewpoint elucidates major components of the proposed rules about controlled substance prescribing in telehealth, highlights evolving considerations with the US Drug Enforcement Agency’s approach, and offers potential improvements before finalization of the rules.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have